Printer Friendly

CLINTEC NUTRITION RECEIVES FDA CLEARANCE TO TEST ORAL FORM OF ITS PROCYSTEINE COMPOSITION IN CLINICAL TRIALS WITH HIV POSITIVE PATIENTS

 CLINTEC NUTRITION RECEIVES FDA CLEARANCE TO TEST ORAL FORM OF ITS PROCYSTEINE COMPOSITION IN CLINICAL TRIALS WITH HIV POSITIVE PATIENTS
 DEERFIELD, Ill., May 21 /PRNewswire/ -- Clintec Nutrition Company announced today that it has received clearance from the Food and Drug Administration (FDA) to begin Phase I controlled human clinical trials with a new oral form of Procysteine (tm), a precursor of the naturally occurring amino acid, L-cysteine. Procysteine stimulates the synthesis of glutathione, which is essential for normal cellular function. Glutathione has been shown to inhibit replication of the Human Immunodeficiency Virus (HIV) in cell culture.
 AIDS clinics at the University Hospitals of Cleveland; Roger Williams General Hospital, Providence, Rhode Island; and the division of Clinical Pharmacology of The Johns Hopkins Medical Institution, Johns Hopkins Hospital, Baltimore, will begin a toleration, pharmacokinetics and efficacy study with a capsule form of Procysteine.
 Clintec recently completed a Phase I trial with intravenously administered Procysteine in HIV positive, symptom-free subjects. Since intravenous drug administration is not optimal for a chronic condition such as HIV infection or AIDS, Clintec has developed and will now test the Procysteine capsules.
 According to Dr. Dennis Goldberg, the leader of Clintec Nutrition Company's Procysteine project, orally administered Procysteine appears to have been well tolerated and raises tissue and leukocyte glutathione levels in animals. Procysteine is an odorless, tasteless, inactive prodrug until intracellular conversion to cysteine. Other glutathione stimulating drugs such as N-acetylcysteine are also under investigation for AIDS therapy.
 Initial discovery of the glutathione-stimulating effect of Procysteine was made by Drs. Alton Meister and Joanne Williamson in the Department of Biochemistry, Cornell University Medical College, New York, N.Y. Clintec obtained the exclusive rights and all Procysteine patents from the Cornell Research Foundation Inc. Clintec Nutrition Company has been issued patents and has pending a number of patent applications relating to various clinical indications using the Procysteine composition.
 Clintec Nutrition Company, a joint venture between Baxter Healthcare Corp. and Nestle S.A., is a worldwide leader in clinical nutrition, providing a full line of parenteral and enteral nutrition products.
 -0- 5/21/92
 /CONTACT: Nancy Schmelkin of Clintec Nutrition, 708-317-2948/ CO: Clintec Nutrition Company ST: Illinois IN: MTC SU:


KD -- NY050 -- 2776 05/21/92 11:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1992
Words:370
Previous Article:CMS ENERGY BOARD OF DIRECTORS RE-ELECTED
Next Article:NATIONWIDE HEALTH PROPERTIES INC. CONTINUES TO INCREASE ITS REGULAR QUARTERLY DIVIDEND -- DECLARES $.55 PER SHARE
Topics:


Related Articles
HUMAN CLINICAL TRIALS OF VIAGENE'S GENE TRANSFER THERAPEUTIC FOR AIDS CLEARED BY FDA ADVISORY COMMITTEE
FREE RADICAL SCIENCES INC. COMPLETES $6.5 MILLION FINANCING
TRANSCEND THERAPEUTICS COMPLETES $2M PRIVATE FINANCING
Amarillo Biosciences' Board of Directors Approves Additional Clinical Study Funding
Orphan Drug Designation Received.
Hollis-Eden Receives Clearance From South African Government to Initiate a Clinical Trial with Transmucosal (Buccal) Formulation of Investigational...
Food and Drug Administration Grants Fast Track Status for Panacos Pharmaceuticals' HIV Drug Candidate PA-457, the First-in-Class Maturation Inhibitor.
Amarillo Biosciences Files Investigational New Drug (IND) Application to Test Oral Interferon Alpha in Oral Warts in HIV-Positive Subjects.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters